Mon panier

NT-3

NT-3 Informations sur la molécule

Nom anglaisNeurotrophin-3Nombre de médicaments commercialisés0
Nombre de médicaments cliniques2Alias de la cibleNeurotrophin 3,NGF2,NT-3,Neurotrophic factor,HDNF,Nerve growth factor 2,NGF-2,NT3
Phase de R&D la plus avancéePhase 2 Clinical
Nom anglaisNeurotrophin-3
Alias de la cibleNeurotrophin 3,NGF2,NT-3,Neurotrophic factor,HDNF,Nerve growth factor 2,NGF-2,NT3
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques2
Phase de R&D la plus avancéePhase 2 Clinical

NT-3 Liste de produits

  • Attribut

    Protein (1)

  • Bibliothèque de produits

    En ligne (1)

  • Espèces

    Human (1)

  • Étiquette

    Tag Free (1)

  • Marqueur

    Unconjugated (1)

Numéro de produitEspècesSystème d'expressionDescription du produitStructure protéiquePuretéCaractéristiquesPré-commande/Commande
NT3-H5213
Human
HEK293
Human NT-3 Protein, Tag Free, low endotoxin (HPLC verified)
Ajouter au panier
Quantité totale1
  • 1

NT-3Contexte de la molécule

Neurotrophin-3 (NT-3), encoded by the NTF3 gene, is a member of the NGF family of neurotrophic factors (also named neurotrophins). The neurotrophin family is comprised of at least four proteins including NGF, BDNF, NT-3, and NT-4/5. These secreted cytokines are synthesized as prepropeptides that are proteolytically processed to generate the mature proteins. Their functions including supporting the survival and differentiation of existing neurons, encouraging the growth and differentiation of new neurons and synapses, are required in both the central and the peripheral nervous systems. NT-4 signals predominantly through the TrkB receptor tyrosine kinase. NTF3-deficient mice generated by gene targeting display severe movement defects of the limbs. The mature peptide of this protein is identical in all mammals examined including human, pig, rat and mouse.

NT-3Alias de la molécule

HDNF,Nerve growth factor 2,NGF-2,Neurotrophic factor,NTF3,NT3.Neurotrophin3

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
scAAV1.tMCK.NTF3Phase 2 ClinicalNationwide Children'S Hospital, Sarepta Therapeutics IncCharcot-Marie-Tooth Disease
Details
LEVI-04LEVI-04; p75NTR-FcPhase 2 ClinicalLeviceptArthritis; Joint Diseases; Musculoskeletal Diseases; Osteoarthritis; Osteoarthritis, Knee; Pain; Rheumatic Diseases
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments cliniques